Concepedia

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Jochen Rentschler, R. Kaiser, Nicolas Rouyrre, Dirk Trommeshauser, Cornelia E. Hoesl, Gerd Munzert

Journal of Clinical Oncology · 2008 · 156 citations · 14 references

DOIFull text

Open access

Abstract

The MTD of BI 2536 when administered as a single-dose, 1-hour infusion was 200 mg; BI 2536 was well tolerated and showed a favorable pharmacokinetic profile. Antitumor activity of BI 2536 was observed.

References

14

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

, , +17

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.4K citations

, , +14

BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo

Martin Steegmaier, Matthias Hoffmann, Anke Baum et al. · Current Biology · 2007 · 839 citations · Full text

, , +9

The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1

Péter Lénárt, Mark Petronczki, Martin Steegmaier et al. · Current Biology · 2007 · 675 citations · Full text

, , +12

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Richard Simon, Larry Rubinstein, Susan G. Arbuck et al. · JNCI Journal of the National Cancer Institute · 1997 · 632 citations · Full text